Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose-escalation, Phase I Study to Determine the Maximum Tolerated Dose, Recommended Dose, Pharmacokinetics, and Pharmacodynamics of the Proteosome Inhibitor CEP 18770 Given Intravenously as Single Agent in Patients With Advanced Solid Tumours or Non-Hodgkin's Lymphomas

NCT00572637 is registered in ClinicalTrials.gov with Ethical Oncology Science as lead sponsor.

NCT NCT00572637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00572637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose-escalation, Phase I Study to Determine the Maximum Tolerated Dose, Recommended Dose, Pharmacokinetics, and Pharmacodynamics of the Proteosome Inhibitor CEP 18770 Given Intravenously as Single Agent in Patients With Advanced Solid Tumours or Non-Hodgkin's Lymphomas
Lead sponsor
Ethical Oncology Science
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2007
Completion date
March 31, 2010
Enrollment
55 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, non-hodgkin, solid tumors